Phaseline

Companies › Damora Therapeutics

Damora Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DMR-001
CALR-mutant myeloproliferative neoplasm targeted therapy
–Phase 1Myeloproliferative Neoplasms (MPNs)Jun 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07849231DMR-001Phase 1Myeloproliferative Neoplasms (MPNs)OncologyJun 2030

From the company's SEC filings

Cash and short-term investments of $528m on 2026-09-30; operating cash outflow about $80m a year; runway about 79 months at that burn, to May 2033

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.